查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464750

先天性高胰島素血症治療藥物市場：按適應症類型、治療方法、給藥途徑、分銷管道和最終用戶分類 - 全球預測 2024-2030

Congenital Hyperinsulinism Treatment Market by Indication Type, Treatment, Route of Administration, Distribution Channel, End-Users - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年先天性高胰島素血症治療藥物市場規模為1.8253億美元，2024年達1.922億美元，2030年達2.6764億美元，複合年成長率為5.61%。

先天性高胰島素血症（CHI）是一種複雜的病理，其特徵是嬰幼兒和兒童胰島素分泌過多，導致嚴重低血糖。 CHI 的治療選擇是多方面的，旨在將血糖值維持在正常範圍內並預防低血糖發作。其中包括二氮嗪、Octreotide、蘭瑞肽等新藥等藥物治療，以及嚴重病例的手術介入。擴大 CHI 治療選擇的主要因素包括診斷技術的進步、對疾病遺傳和分子基礎的了解的加深以及針對胰島素分泌特定途徑的新型藥物的開發。然而，CHI的治療有挑戰，包括二氮嗪可能產​​生液體儲存和Octreotide胃腸道症狀等副作用，以及症狀緩解不完全和低血糖復發的風險。應對這些挑戰需要繼續研究更有針對性和微創的治療策略、基於基因分析的個人化醫療以及開發更有效和更安全的藥物。可以即時調節胰島素產生和分泌的人工胰臟系統的出現，為管理 CHI 提供了突破性方法，並為 CHI 提供了先進的治療方法。

主要市場統計
基準年[2023] 1.8253 億美元
預測年份 [2024] 1.922 億美元
預測年份 [2030] 2.6764億美元
複合年成長率（%） 5.61%

適應症類型 治療非典型 CHI 需要個別化方法

非典型先天性高胰島素血症是 CHI 患者的一個子集，具有不常見的基因突變，其症狀和嚴重程度各不相同。這種形式的疾病通常需要結合藥物治療和監測策略的靈活治療方法。瀰漫性先天性胰島素分泌過多的特徵是整個胰臟胰島素細胞的異常行為，需要全身性治療方法。由於細胞受累的廣泛性，手術是最後的手段，藥物治療（包括二氮嗪和Octreotide）是主要治療方法。局部先天性高胰島素血症的特徵是胰臟內局部存在異常細胞。作為一種治療策略，首選手術切除受影響區域，並且有可能治癒。診斷影像和手術技術的進步極大地改善了局部CHI 的治療結果。

最終用戶醫院需要對先天性高胰島素血症進行多種治療

對於需要小手術介入或門診手術的較輕的先天性高胰島素血症病例，首選門診手術中心 (ASC)。 ASC 對患者和看護者很有吸引力，因為它們高效、成本低且出院時間短。 ASC 正在配備先進的醫療技術，現在能夠提供以前只能在醫院提供的各種服務。醫院是治療嚴重先天性高胰島素血症病例的主要選擇，特別是需要複雜手術介入或加護治療的病例。醫院提供一站式綜合護理，包括診斷、手術和術後護理。該醫院擁有廣泛的設備和專家，非常適合處理更複雜的先天性高胰島素血症病例。選擇專科診所對先天性高胰島素血症的治療進行專門治療，特別是在持續治療和介入後追蹤方面。這些診所通常提供高水準的專業知識和個人化的護理計劃。

區域洞察

在美洲，先天性高胰島素疾病市場十分強勁，尤其是在美國，該市場非常注重研究和開發，導致先進治療方法的採用率很高，並且大型製藥企業積極進入。該地區的公司正在投資各種研發 (R&D) 活動，以支持引進先進的先天性高胰島素血症治療方法。亞太地區的特點是在意識提高和醫療基礎設施改善的推動下實現快速成長，特別是在中國等國家和醫療保健領域。中東和非洲在醫療保健的取得和品質方面存在差異。歐洲公司在該市場佔有重要地位，這表明該地區對創新治療方法和國際合作的開放態度。政府對研究活動的支持擴大了該地區醫院和專科診所的研究活動。

FPNV定位矩陣

FPNV定位矩陣對於評估先天性高胰島素血症藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對先天性高胰島素血症治療藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.先天性高胰島素血症治療藥物市場規模及預測如何？

2.先天性高胰島素血症治療藥物市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.先天性高胰島素血症治療藥物市場的技術趨勢和法規結構是什麼？

4.先天性高胰島素血症治療藥物市場主要供應商的市場佔有率是多少？

5.進入先天性高胰島素血症藥物市場的合適型態和策略性手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 先天性高胰島素血症盛行率增加
      • 政府努力促進先天性高胰島素血症的診斷
    • 抑制因素
      • 先天性高胰島素血症的報銷有限
    • 機會
      • 持續研究和開發以推進先天性高胰島素血症的治療
      • 治療先天性高胰島素血症的藥物核准進展
    • 任務
      • 診斷挑戰和可能的治療併發症
  • 市場區隔分析
    • 適應症類型：非典型CHI的治療需要更個人化的方法
    • 最終使用者：先天性高胰島素血症在醫院需要多種治療方法
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章先天性高胰島素血症治療藥物市場（依適應症類型）

  • 非典型先天性高胰島素血症
  • 瀰漫性先天性高胰島素血症
  • 局部先天性高胰島素血症

第7章先天性高胰島素血症治療藥物市場（依治療）

  • 膳食管理
  • 藥物
  • 手術治療

第8章先天性高胰島素血症治療藥物市場：依給藥途徑

  • 口服
  • 胃腸外的

第9章先天性高胰島素血症治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章先天性高胰島素血症治療藥物市場：依最終使用者分類

  • 門診手術中心
  • 醫院
  • 專科診所

第11章 北美和南美先天性高胰島素血症治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區先天性高胰島素血症治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章 歐洲、中東和非洲先天性高胰島素血症治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • C-Path 和先天性高胰島素症國際宣布資料共用協議
    • Zealand Pharma 向美國FDA 提交用於治療先天性高胰島素血症的升糖素新藥申請
    • Rhythm Pharmaceuticals 宣布收購 Xinvento BV 和臨床實驗藥物組合
  • 戰略分析和建議

第15章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-F97DD5A7D994

[192 Pages Report] The Congenital Hyperinsulinism Treatment Market size was estimated at USD 182.53 million in 2023 and expected to reach USD 192.20 million in 2024, at a CAGR 5.61% to reach USD 267.64 million by 2030.

Congenital hyperinsulinism (CHI) is a complex condition characterized by excessive insulin production in infants and children, leading to severe hypoglycemia. CHI treatment options are multifaceted, aiming to maintain blood glucose levels within a normal range and prevent hypoglycemic episodes. These include medical therapies such as diazoxide, octreotide, and newer drugs like lanreotide, as well as surgical interventions in more severe cases. The major factors contributing to the expansion of CHI treatment options include advancements in diagnostic methodologies, improved understanding of the genetic and molecular bases of the disease, and the development of novel pharmacological agents targeting specific pathways involved in insulin secretion. However, treatments for CHI come with challenges, including potential side effects, such as fluid retention with diazoxide or gastrointestinal symptoms with octreotide, and the risk of incomplete relief from symptoms or hypoglycemia recurrence. Addressing these challenges involves ongoing research into more targeted and less invasive therapeutic strategies, personalized medicine based on genetic profiling, and developing more effective and safer drugs. The advent of artificial pancreas systems that could regulate insulin production and release in real-time offers a transformative approach to managing CHI, providing advanced treatment for the condition.

KEY MARKET STATISTICS
Base Year [2023] USD 182.53 million
Estimated Year [2024] USD 192.20 million
Forecast Year [2030] USD 267.64 million
CAGR (%) 5.61%

Indication Type: Need for a more personalized approach to treat Atypical CHI

Atypical congenital hyperinsulinism represents a subset of CHI patients with less common genetic mutations, leading to variable presentation and severity. This form requires flexible, tailored treatment approaches, often involving a combination of medical therapy and monitoring strategies. Diffuse Congenital hyperinsulinism is characterized by insulin cells across the pancreas behaving abnormally, necessitating a systemic treatment approach. Surgery can be a last resort due to the pervasive nature of cell involvement, and medication management, including diazoxide and octreotide, remains the primary treatment. Focal congenital hyperinsulinism is marked by a localized region of abnormal cells within the pancreas. The preferred treatment strategy is surgical removal of the affected area, offering a potential cure. Advances in imaging and surgical techniques have greatly enhanced the treatment outcomes for focal CHI.

End-Users: Need for a diverse range of treatments for congenital hyperinsulinism in hospitals

Ambulatory surgery centers (ASCs) are preferred for less severe cases of congenital hyperinsulinism that necessitate minor surgical interventions or outpatient procedures. The efficiency, lower cost, and faster discharge times make ASCs attractive for patients and caregivers. ASCs are increasingly equipped with advanced medical technologies that enable them to offer a range of services that were traditionally available only in hospital settings. Hospitals are the primary choice for managing severe cases of congenital hyperinsulinism, especially those requiring complex surgical interventions or intensive care. They offer comprehensive care, including diagnostics, surgery, and post-operative management, under one roof. Hospitals are equipped with a broad range of facilities and specialists, making them well-suited for handling congenital hyperinsulinism cases with higher levels of complexity. Specialty clinics are chosen for their specialized care in managing congenital hyperinsulinism, particularly for ongoing management and follow-up post-intervention. These clinics often provide a high level of expertise and personalized care plans.

Regional Insights

In the Americas, the congenital hyperinsulinism market is robust, with a high adoption rate of advanced treatments and active participation from leading pharmaceuticals, driven by a strong focus on research and development, particularly in the United States. Companies in the region have invested in various research & development (R&D) activities to support the introduction of advanced congenital hyperinsulinism treatment. The APAC scenario is marked by rapid growth fueled by increasing awareness and improving healthcare infrastructure, especially in countries such as China and India. EMEA presents a mixed environment with strong healthcare systems in Europe facilitating access to treatments and encouraging clinical trials, while the Middle East and Africa grapple with variability in healthcare access and quality. European companies have a significant presence in the market, indicative of the region's openness to innovative treatments and international collaborations. With government support for research activities, the region is witnessing an expansion of congenital hyperinsulinism treatment activities in hospitals & specialty clinics.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Congenital Hyperinsulinism Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Congenital Hyperinsulinism Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Congenital Hyperinsulinism Treatment Market, highlighting leading vendors and their innovative profiles. These include Crinetics Pharmaceuticals, Inc., Eiger Biopharmaceuticals Inc., Hanmi Pharmaceutical Company, Hua Medicine (Shanghai) Co., Ltd., Novartis AG, Rezolute, Inc., Rhythm Pharmaceuticals, Inc., Twist Bioscience Corporation, Xeris Biopharma Holdings, Inc., XOMA Corporation, and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Congenital Hyperinsulinism Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication Type
    • Atypical Congenital Hyperinsulinism
    • Diffuse Congenital Hyperinsulinism
    • Focal Congenital Hyperinsulinism
  • Treatment
    • Dietary Management
    • Drugs
      • Diazoxide
      • Glucagon
      • Nifedipine
      • Octreotide
    • Surgical Intervention
  • Route of Administration
    • Oral
    • Parenteral
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End-Users
    • Ambulatory Surgery Centers
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Congenital Hyperinsulinism Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Congenital Hyperinsulinism Treatment Market?

3. What are the technology trends and regulatory frameworks in the Congenital Hyperinsulinism Treatment Market?

4. What is the market share of the leading vendors in the Congenital Hyperinsulinism Treatment Market?

5. Which modes and strategic moves are suitable for entering the Congenital Hyperinsulinism Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in prevalence of congenital hyperinsulinism disease
      • 5.1.1.2. Government initiatives promoting congenital hyperinsulinism diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursement available for congenital hyperinsulinism
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D for advancing treatment of congenital hyperinsulinism
      • 5.1.3.2. Emerging approval of congenital hyperinsulinism treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Diagnostic challenges and possible complications of the treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Indication Type: Need for a more personalized approach to treat Atypical CHI
    • 5.2.2. End-Users: Need for a diverse range of treatments for congenital hyperinsulinism in hospitals
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Congenital Hyperinsulinism Treatment Market, by Indication Type

  • 6.1. Introduction
  • 6.2. Atypical Congenital Hyperinsulinism
  • 6.3. Diffuse Congenital Hyperinsulinism
  • 6.4. Focal Congenital Hyperinsulinism

7. Congenital Hyperinsulinism Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Dietary Management
  • 7.3. Drugs
  • 7.4. Surgical Intervention

8. Congenital Hyperinsulinism Treatment Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Congenital Hyperinsulinism Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Congenital Hyperinsulinism Treatment Market, by End-Users

  • 10.1. Introduction
  • 10.2. Ambulatory Surgery Centers
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas Congenital Hyperinsulinism Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Congenital Hyperinsulinism Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Congenital Hyperinsulinism Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. C-Path and Congenital Hyperinsulinism International Announce Data Sharing Agreement
    • 14.3.2. Zealand Pharma Submits New Drug Application to US FDA for Dasiglucagon In Congenital Hyperinsulinism
    • 14.3.3. Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CONGENITAL HYPERINSULINISM TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CONGENITAL HYPERINSULINISM TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. CONGENITAL HYPERINSULINISM TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. CONGENITAL HYPERINSULINISM TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CONGENITAL HYPERINSULINISM TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ATYPICAL CONGENITAL HYPERINSULINISM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ATYPICAL CONGENITAL HYPERINSULINISM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIFFUSE CONGENITAL HYPERINSULINISM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIFFUSE CONGENITAL HYPERINSULINISM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY FOCAL CONGENITAL HYPERINSULINISM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY FOCAL CONGENITAL HYPERINSULINISM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIAZOXIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIAZOXIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY GLUCAGON, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY NIFEDIPINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY NIFEDIPINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY OCTREOTIDE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 101. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 102. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 103. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 104. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 111. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 112. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 113. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 116. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 123. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 124. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 125. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 128. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 148. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 150. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 152. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 154. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 156. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 157. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 160. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 161. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 162. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 163. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 164. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 165. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 168. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 169. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 172. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 173. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 174. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 175. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 176. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 177. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 180. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 181. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 184. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 185. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 186. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 187. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 188. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 189. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 192. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 193. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 196. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 197. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 198. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 199. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 200. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 201. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 204. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 205. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 208. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 209. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 210. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 211. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 212. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 213. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 214. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 215. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 216. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 220. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 222. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 224. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 226. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 228. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 229. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 232. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 233. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 234. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 235. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 236. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 237. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 238. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 239. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 240. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 253. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 256. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 257. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 258. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 259. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 260. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 261. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 262. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 263. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 264. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 265. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 268. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 269. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 270. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 271. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 272. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 273. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 274. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 275. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 276. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 277. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2023 (USD MILLION)
  • TABLE 280. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2024-2030 (USD MILLION)
  • TABLE 281. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
  • TABLE 282. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
  • TABLE 283. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 284. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 285. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 286. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 287. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD MILLION)
  • TABLE 288. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET S